Nursing Care for Children with Thalassemia

Thalassemia is one of the most common inherited blood disorders in children worldwide, particularly prevalent in Mediterranean, Middle Eastern, South Asian, and African populations. This genetic condition disrupts hemoglobin production, leading to chronic anemia that ranges from mild to life-threatening. For paediatric nurses, understanding thalassemia’s complexities is essential for delivering effective, compassionate care to affected children and their families.

Understanding thalassemia and its types 🔗

Thalassemia occurs when the body cannot produce adequate amounts of hemoglobin-the protein in red blood cells responsible for carrying oxygen throughout the body. Hemoglobin molecules consist of protein chains called alpha and beta chains, and thalassemia results from gene changes that affect the production of either chain.

There are two main types based on which globin chain is affected:

Alpha thalassemia: Caused by deletions or mutations in one or more of the four alpha-globin genes. The severity depends on how many genes are affected. Alpha thalassemia major, where all four alpha genes are missing, is a very serious form that develops before birth and often results in stillbirth or death shortly after delivery without intervention.

Beta thalassemia: Results from mutations in one or both of the beta-globin genes. This type is classified into three categories:

Thalassemia minor (trait): Children with thalassemia minor have one abnormal gene and typically experience no symptoms except mild anemia. They do not require treatment but can pass the gene to their children.

Thalassemia intermedia: This type causes mild to severe anemia and may require blood transfusions during illness or stress.

Thalassemia major (Cooley’s anemia): The most severe form, where both genes are affected. Children with beta thalassemia major have life-threatening anemia requiring regular blood transfusions and comprehensive medical care throughout their lives.

Clinical manifestations in children 🔗

Symptoms of beta thalassemia major typically appear when an infant is between 6 and 24 months of age. Early signs include poor growth, feeding difficulties, irritability, and progressive pallor.

As the disease progresses without treatment, children may develop:

Severe anemia: Manifesting as fatigue, weakness, pale skin, and shortness of breath.

Hepatosplenomegaly: Without treatment, the spleen, liver, and heart become enlarged as they work to compensate for inadequate red blood cell production.

Skeletal changes: The bone marrow expands in an attempt to produce more red blood cells, causing characteristic facial bone deformities, frontal bossing, and dental abnormalities. Bones may become thin and brittle.

Growth retardation: Chronic anemia impairs physical growth and delayed puberty is common.

Jaundice: Rapid destruction of defective red blood cells leads to elevated bilirubin levels and yellowing of skin and eyes.

Diagnostic evaluation 🔗

Accurate diagnosis of thalassemia relies on a combination of clinical assessment and laboratory investigations. Moderate and severe thalassemia is usually diagnosed in early childhood within the first two years of life.

Complete blood count and peripheral smear 🔗

The initial step involves a CBC, which typically reveals microcytic, hypochromic anemia. Peripheral smear examination shows target cells, teardrop cells, and cells with basophilic stippling. Red blood cells appear smaller than normal with reduced hemoglobin content.

Iron studies 🔗

Serum ferritin and transferrin levels help differentiate thalassemia from iron deficiency anemia. Unlike iron deficiency, thalassemia typically presents with normal or elevated ferritin levels. This distinction is crucial because unnecessary iron supplementation in thalassemia patients can lead to dangerous iron overload.

Hemoglobin electrophoresis 🔗

Hemoglobin electrophoresis or equivalent techniques quantify different hemoglobin types and can identify characteristic patterns. Beta thalassemia major shows elevated HbF and HbA2 with decreased or absent HbA. However, hemoglobin electrophoresis will not detect abnormalities in silent carriers or those with alpha thalassemia trait.

Genetic testing 🔗

Molecular testing provides definitive diagnosis by identifying specific gene deletions or mutations. This is particularly important for genetic counselling and prenatal diagnosis in at-risk families.

Management: blood transfusion therapy 🔗

Blood transfusion therapy is the primary treatment to prevent death in children with thalassemia major. The goal is to maintain hemoglobin levels that suppress ineffective erythropoiesis and allow normal growth and development.

Transfusion protocols 🔗

Regular transfusions are recommended if hemoglobin falls below 7 g/dL on two occasions. Children typically require transfusions every 2-4 weeks to maintain pre-transfusion hemoglobin above 9-10.5 g/dL.

The product of choice is packed red blood cells that are leukocyte-depleted and matched for red cell antigens including D, C, c, E, e, and Kell to minimize alloimmunization risk.

Nursing responsibilities during transfusion 🔗

Before transfusion, nurses should verify patient identification, confirm blood compatibility, and obtain baseline vital signs. During the procedure, monitoring for transfusion reactions is critical. Signs include fever, chills, rash, back pain, and respiratory distress. After completion, vital signs should be reassessed and the child observed for delayed reactions.

Chelation therapy for iron overload 🔗

Each unit of transfused blood contains approximately 200 mg of iron. Since the body lacks a mechanism to excrete excess iron, organ failure due to iron toxicity is the leading cause of death for thalassemia patients in developed countries.

Iron chelating agents 🔗

Three FDA-approved iron chelators are available: deferoxamine, deferasirox, and deferiprone.

Deferoxamine (Desferal): The longest-used chelator, administered via subcutaneous infusion over 8-12 hours, 5-7 days per week. It is typically withheld until after two years of age because side effects are greater in young children with limited iron stores.

Deferasirox (Exjade): An oral chelator taken once daily as a dispersible tablet, offering improved compliance compared to injectable therapy.

Deferiprone: Another oral option that may provide better penetration into cardiac cells. Combination therapy with deferoxamine and deferiprone has shown additive effects on iron excretion and improved cardiac function.

Monitoring iron levels 🔗

Serum ferritin is routinely measured to monitor iron burden, though liver iron concentration provides more accurate assessment. Serum ferritin levels of 800 ng/mL or higher indicate increased risk of serious iron-related complications. Cardiac MRI T2* imaging helps detect myocardial iron deposition before clinical heart failure develops.

Splenectomy and infection prevention 🔗

Splenectomy may be considered when hypersplenism increases transfusion requirements and prevents adequate iron control with chelation. However, this surgery is generally avoided in children under five years due to increased infection risk.

Infection prevention strategies 🔗

Children who undergo splenectomy face significantly higher risk of overwhelming sepsis. Patients must receive adequate immunisation against Streptococcus pneumoniae, Haemophilus influenzae type B, and Neisseria meningitidis before surgery.

Post-splenectomy prophylactic antibiotics are essential. Parents should be educated about recognising early signs of infection and seeking immediate medical attention for fever or other concerning symptoms.

Comprehensive nursing care 🔗

Nursing interventions for children with thalassemia include health care instructions, psychological support, educational programmes, and counselling. Effective care requires a holistic approach addressing physical, emotional, and developmental needs.

Physical assessment and monitoring 🔗

Regular assessment should include vital signs, growth parameters, signs of anemia, hepatosplenomegaly, and skeletal changes. Nurses must monitor for complications of both the disease and its treatment, including cardiac dysfunction, endocrine abnormalities, and chelation therapy side effects.

Psychosocial support 🔗

Living with thalassemia significantly impacts quality of life. Children may experience boredom, saturation with treatment, and feelings of hopelessness. They often feel different from peers due to physical changes and activity limitations. Nurses should provide emotional support and connect families with counselling resources.

Family education 🔗

Educating families about the disease, treatment regimens, medication administration, and recognising complications empowers them to participate actively in care. Genetic counselling helps families understand inheritance patterns and reproductive options.

Emerging treatments: gene therapy and stem cell transplant 🔗

Bone marrow transplant remains the only established cure for thalassemia. Best outcomes occur when performed in young children before complications develop, using a well-matched sibling donor.

Gene therapy represents a promising newer treatment approach. FDA-approved options like Zynteglo and Casgevy modify patients’ own blood stem cells to produce functional hemoglobin, potentially eliminating the need for lifelong transfusions.

Long-term follow-up care 🔗

Children with thalassemia may need to see specialists including cardiologists, endocrinologists, gastroenterologists, and orthopaedic specialists as complications can affect multiple organ systems. Regular screening for cardiac iron overload, endocrine dysfunction, osteoporosis, and other complications enables early intervention.

The best way for children with thalassemia to live their healthiest life is through regular medical care, including adherence to transfusion and chelation schedules. With comprehensive management, many children with thalassemia can achieve good quality of life and reach adulthood.

What do you think? How can paediatric nurses better support families in managing the emotional burden of a chronic condition like thalassemia while ensuring optimal adherence to complex treatment regimens?

References

1. https://my.clevelandclinic.org/health/diseases/14508-thalassemias
2. https://www.cedars-sinai.org/health-library/diseases-and-conditions—pediatrics/a/alpha-thalassemia-in-children.html
3. https://www.childrenshospital.org/conditions/thalassemia
4. https://www.cedars-sinai.org/health-library/diseases-and-conditions—pediatrics/b/beta-thalassemia-in-children.html
5. https://kidshealth.org/en/parents/beta-thalassemia.html
6. https://www.hopkinsmedicine.org/health/conditions-and-diseases/beta-thalassemia
7. https://www.childrensmn.org/services/care-specialties-departments/cancer-blood-disorders/conditions-and-services/blood-disorders-services/hemoglobinopathy-sickle-cell/thalassemia/
8. https://www.ncbi.nlm.nih.gov/books/NBK587402/
9. https://arupconsult.com/content/thalassemias
10. https://emedicine.medscape.com/article/955496-workup
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC10295575/
12. https://www.cdc.gov/thalassemia/hcp/toolkit/developing-a-transfusion-plan.html
13. https://thalassemia.ucsf.edu/blood-transfusions
14. https://thalassemia.ucsf.edu/chelation-therapy
15. https://thalassemia.ucsf.edu/iron-overload-and-chelation-therapy
16. https://pmc.ncbi.nlm.nih.gov/articles/PMC3033168/
17. https://www.thebloodproject.com/diagnosis-of-thalassemia/
18. https://www.childrens.com/specialties-services/conditions/thalassemia
19. https://www.chla.org/thalassemia
20. https://www.seattlechildrens.org/conditions/thalassemia/